Last updated: September 7, 2026
Ravulizumab-cwvz, marketed as Ultomiris by AstraZeneca’s Alexion unit, has become the company’s principal complement C5 inhibitor and the commercial successor to Soliris. Revenue growth has been driven by conversion from Soliris, expansion into generalized myasthenia gravis and neuromyelitis optica spectrum disorder, and longer dosing intervals. The product’s U.S. biologic exclusivity runs to December 2030, while core patent protection is expected to extend into the mid-2030s, with later method-of-use and formulation claims potentially reaching beyond that period.
What is ravulizumab-cwvz and how is Ultomiris used?
Ravulizumab-cwvz is a long-acting monoclonal antibody that inhibits complement component 5, or C5. Blocking C5 prevents formation of terminal complement complex C5b-9, a mechanism relevant to several complement-mediated diseases.
The U.S. Food and Drug Administration has approved Ultomiris for:
| Indication |
U.S. approval status |
Commercial significance |
| Paroxysmal nocturnal hemoglobinuria, or PNH |
Approved in 2018 |
Initial market and Soliris conversion base |
| Atypical hemolytic uremic syndrome, or aHUS |
Approved in 2019 |
Extends use into renal and thrombotic microangiopathy care |
| Generalized myasthenia gravis, or gMG |
Approved in 2022 |
Adds a larger chronic autoimmune market |
| Neuromyelitis optica spectrum disorder, or NMOSD, in adults who are anti-AQP4 antibody positive |
Approved in 2024 |
Expands the franchise into a second neurological indication |
Ultomiris is administered intravenously at longer intervals than Soliris. For many adult patients, maintenance treatment is given every eight weeks after a loading dose. That schedule reduces infusion frequency and has been central to the product’s conversion strategy. FDA labeling also includes weight-based dosing provisions for pediatric patients and disease-specific regimens. [1]
How has ravulizumab revenue developed?
Ultomiris has moved from a replacement product for Soliris into a multibillion-dollar franchise. AstraZeneca reports product revenue at the brand level rather than publishing a separate revenue line for the active ingredient, ravulizumab-cwvz.
| Fiscal year |
Approximate Ultomiris revenue |
Main growth drivers |
| 2021 |
About $1.5 billion |
PNH conversion and wider global availability |
| 2022 |
About $2.4 billion |
aHUS growth, Soliris switching, gMG launch |
| 2023 |
About $3.4 billion |
Continued switching and neurological expansion |
| 2024 |
About $4.4 billion |
Broader gMG uptake and NMOSD launch contribution |
These figures are rounded from AstraZeneca annual-report disclosures. The trajectory indicates a compound annual growth rate of roughly 40% from 2021 through 2024, although growth should moderate as the main Soliris conversion opportunity matures. [2-5]
Why has Ultomiris displaced Soliris?
The commercial switch is based on dosing convenience, franchise control and lifecycle management.
Soliris generally requires dosing every two weeks after an induction phase. Ultomiris can maintain C5 inhibition with substantially less frequent administration for many patients. Alexion has used the longer interval to migrate existing patients, limit internal cannibalization, and preserve payer and prescriber familiarity with the C5 mechanism.
The principal economic benefit is not only new patient acquisition. It is retention of patients who might otherwise move to competing complement inhibitors or oral therapies.
What markets are driving ravulizumab growth?
PNH and aHUS
PNH remains the anchor indication. Treatment is chronic, the patient population is highly concentrated among specialist centers, and complement inhibition can materially reduce hemolysis and disease complications.
aHUS contributes a smaller patient population but supports high per-patient revenue. Treatment decisions are influenced by disease severity, renal outcomes, transplant considerations and the need for rapid complement control.
Both indications have benefited from Soliris-to-Ultomiris conversion. The conversion opportunity is finite, so future growth depends more heavily on new indications and geographic expansion.
Generalized myasthenia gravis
The gMG opportunity is strategically important because it places ravulizumab in a larger immunology market with multiple biologic competitors. Ultomiris competes with:
- Efgartigimod alfa, marketed as Vyvgart.
- Rozanolixizumab, marketed as Rystiggo.
- Eculizumab, marketed as Soliris.
- Conventional immunosuppressive therapy.
- Other targeted therapies in development.
The gMG market has a broader prescriber base than PNH and a larger potential patient pool. It also has more treatment alternatives, making formulary access, clinical positioning and total cost of care more important.
NMOSD
The NMOSD approval adds a specialized neurological indication in which anti-AQP4 antibody status helps define the treated population. Competition includes inebilizumab, satralizumab and eculizumab.
NMOSD is unlikely to match PNH or gMG in absolute patient volume, but it strengthens the commercial case for ravulizumab by adding another chronic indication that can use the product’s extended dosing schedule.
How does ravulizumab compare with competing complement inhibitors?
| Product |
Active ingredient |
Company |
Administration or profile |
Competitive position |
| Ultomiris |
Ravulizumab-cwvz |
Alexion/AstraZeneca |
Long-acting C5 antibody; mainly IV dosing |
Broad indication base and eight-week adult maintenance schedule |
| Soliris |
Eculizumab |
Alexion/AstraZeneca |
Shorter-interval C5 antibody |
Established standard and source of conversion patients |
| Empaveli |
Pegcetacoplan |
Apellis |
C3 inhibitor; subcutaneous administration |
Competes in PNH and addresses upstream complement activity |
| Fabhalta |
Iptacopan |
Novartis |
Oral factor B inhibitor |
Oral convenience and upstream pathway differentiation |
| Piasky |
Crovalimab-akkz |
Roche |
Long-acting C5 inhibitor |
Competes on dosing frequency and delivery options |
| Vyvgart |
Efgartigimod alfa |
argenx |
FcRn antagonist |
Major gMG competitor with a different mechanism |
Ravulizumab’s strongest competitive advantages are established physician familiarity, a broad complement franchise, long-term clinical experience inherited from Soliris, and less frequent dosing than eculizumab. Its main weaknesses are infusion infrastructure, high treatment cost and exposure to newer oral or subcutaneous products.
What is the FDA regulatory status and biologic exclusivity timeline?
Ravulizumab-cwvz is a licensed biologic reference product. It is not regulated as a conventional small-molecule drug under an abbreviated new drug application.
| Event |
Date |
| Original U.S. approval for PNH |
December 21, 2018 |
| Four-year BPCIA biosimilar filing restriction |
December 21, 2022 |
| Twelve-year reference-product exclusivity |
December 21, 2030 |
| Potential pediatric extension |
Could add six months if statutory conditions are satisfied |
The BPCIA permits a biosimilar applicant to submit an application after four years from first licensure, but FDA approval generally cannot take effect until 12 years after first licensure. Patent settlements can delay or shape commercial entry beyond the statutory exclusivity date. [6]
Does Paragraph IV apply to ravulizumab?
No. Paragraph IV certifications apply to patents listed in the Orange Book for small-molecule drug products. A biosimilar applicant for ravulizumab would use the BPCIA patent-dispute process, commonly called the patent dance, rather than filing an ANDA Paragraph IV certification.
What patents protect ravulizumab-cwvz?
The protection profile is built from several patent groups:
- Antibody and antibody-sequence claims.
- C5-binding and complement-inhibition claims.
- Therapeutic-use claims for PNH, aHUS, gMG and NMOSD.
- Dosing-interval and patient-selection claims.
- Formulation and stable liquid-composition claims.
- Manufacturing and process claims.
The core U.S. patent estate is generally expected to protect the product into the mid-2030s. Some later-filed use, dosing and formulation patents may extend beyond the core composition patents, subject to validity, enforceability and statutory patent-term adjustment.
What is the Orange Book status of Ultomiris?
Ultomiris is a biologic, so its principal U.S. patent and exclusivity information is evaluated through the FDA’s Purple Book and the BPCIA framework rather than the conventional Orange Book system used for small-molecule drugs. The FDA’s Purple Book identifies the reference product and any approved biosimilar or interchangeable product. [7]
The practical patent question is therefore not whether an ANDA applicant has filed Paragraph IV litigation. It is whether a biosimilar applicant has completed BPCIA disclosures, whether the parties have initiated patent litigation, and whether a settlement controls the earliest commercial launch date.
How strong is the patent estate for ravulizumab?
The estate is commercially strong but not invulnerable.
Strengths
- The antibody is a complex biologic with sequence, structure and functional claim opportunities.
- Multiple indications create separate method-of-use positions.
- Dosing and patient-selection patents can complicate biosimilar launch planning.
- Manufacturing know-how and analytical comparability create practical barriers beyond patent expiration.
- The product has a long commercial runway before statutory biologic exclusivity expires.
Weaknesses
- A biosimilar does not need to reproduce every manufacturing step if it demonstrates analytical and clinical similarity.
- Later method-of-use patents may not block all uses of a biosimilar.
- Composition patents can face validity challenges based on prior antibodies, written description, enablement or obviousness.
- Competitors can bypass some ravulizumab claims with different complement targets or delivery systems.
Patent protection is therefore stronger against direct product substitution than against market share erosion by oral, subcutaneous or upstream complement therapies.
Which companies are challenging or competing with Ultomiris?
No approved ravulizumab biosimilar was identified in the cited FDA reference-product materials. The main competitive threat is not limited to biosimilar entry.
Direct and near-direct competitors
Roche’s crovalimab is the closest direct commercial competitor because it also targets C5 and is designed for less frequent administration. Novartis’ iptacopan presents a different challenge by offering oral administration and upstream factor B inhibition in PNH. Apellis’ pegcetacoplan competes through C3 inhibition and subcutaneous delivery.
Indication-specific competitors
In gMG, argenx’s Vyvgart and UCB’s Rystiggo compete for chronic biologic treatment. In NMOSD, inebilizumab and satralizumab compete for the same specialty population. These products can reduce Ultomiris growth without infringing ravulizumab patents.
What generic or biosimilar launch risks exist?
The earliest legally relevant U.S. biosimilar approval window begins after December 2030, assuming no enforceable patent barrier delays approval. Commercial launch could occur later if:
- Core patents remain enforceable beyond the exclusivity date.
- A biosimilar applicant settles with AstraZeneca.
- Litigation produces an injunction or damages risk.
- The applicant initially launches only non-patent-protected indications.
- Interchangeability or physician adoption remains limited.
The launch risk is likely to develop in stages. Soliris faces earlier erosion and may lose strategic importance before Ultomiris. Ultomiris faces a later direct biosimilar event but earlier indirect pressure from competing complement mechanisms.
How does ravulizumab affect AstraZeneca’s revenue trajectory?
Ultomiris is one of AstraZeneca’s most important growth products within Alexion. It offsets the long-term decline risk associated with Soliris and provides a high-value base for expansion into neurological autoimmune disease.
The revenue profile should evolve through four phases:
| Phase |
Expected commercial pattern |
| 2021-2024 |
Rapid growth from Soliris switching and new indications |
| 2025-2027 |
Continued gMG and NMOSD penetration; slower conversion growth |
| 2028-2030 |
Mature franchise economics before statutory biologic exclusivity expires |
| After 2030 |
Greater biosimilar, patent and alternative-mechanism pressure |
Revenue exposure is concentrated because treatment costs are high and patient populations are specialized. Pricing pressure, payer restrictions and changes in complement-treatment sequencing could affect growth before patent expiry.
What litigation and settlement issues matter?
The major legal pathway is BPCIA biosimilar litigation rather than Orange Book Paragraph IV litigation. Key legal milestones will include:
- Biosimilar application disclosure.
- Exchange of patent information under the BPCIA.
- Patent-infringement complaints.
- Claims involving composition, formulation, dosing and methods of use.
- Settlement terms covering launch timing and patent licenses.
- Possible disputes over interchangeability and substitution.
No public settlement terms are included here as an established commercial constraint on ravulizumab-cwvz. A settlement could set the effective market-entry date even if the relevant patents expire later.
Key Takeaways
- Ravulizumab-cwvz is marketed as Ultomiris by Alexion, AstraZeneca’s rare-disease unit.
- Revenue has increased from roughly $1.5 billion in 2021 to about $4.4 billion in 2024.
- Growth has come from Soliris conversion, gMG, NMOSD and continued PNH and aHUS demand.
- U.S. biologic exclusivity runs through December 21, 2030.
- Paragraph IV does not apply; biosimilar disputes proceed under the BPCIA.
- Core patent protection is expected to extend into the mid-2030s, with later use and formulation claims potentially extending further.
- The main near-term commercial threats are crovalimab, iptacopan, pegcetacoplan and competing gMG biologics, not only future biosimilars.
- Ultomiris remains a major AstraZeneca growth asset, but growth should moderate as Soliris conversion matures.
FAQs
When can the first ravulizumab biosimilar reach the U.S. market?
FDA approval generally cannot become effective before December 21, 2030, the end of the 12-year reference-product exclusivity period, unless a statutory exception applies.
Is ravulizumab a biosimilar of eculizumab?
No. Ravulizumab is a distinct monoclonal antibody engineered for longer duration. It is the active ingredient in Ultomiris, while eculizumab is the active ingredient in Soliris.
What drug is most likely to challenge Ultomiris in PNH?
Iptacopan presents a significant commercial challenge because it is an oral factor B inhibitor. Crovalimab is the closest direct C5 competitor, while pegcetacoplan competes through upstream C3 inhibition and subcutaneous administration.
Does Ultomiris have an Orange Book patent expiration date?
Not in the same manner as a conventional small-molecule drug. Ultomiris is a biologic, so the relevant framework is the FDA Purple Book and BPCIA, together with the underlying U.S. patent estate.
What is the largest long-term risk to Ultomiris revenue?
The largest risk is combined erosion from alternative complement mechanisms, more convenient delivery systems and biosimilar entry after 2030. Patent expiry alone does not determine the commercial trajectory.
References
- U.S. Food and Drug Administration. (2024). Ultomiris (ravulizumab-cwvz) prescribing information.
- AstraZeneca. (2022). Annual report and Form 20-F 2021.
- AstraZeneca. (2023). Annual report and Form 20-F 2022.
- AstraZeneca. (2024). Annual report and Form 20-F 2023.
- AstraZeneca. (2025). Annual report and Form 20-F 2024.
- U.S. Food and Drug Administration. (2024). Biologics Price Competition and Innovation Act of 2009.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
